Ryvu Therapeutics - Edison Group

Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

VolitionRx

MCap

USD76m

Last close

USD0.81

▲ 0.14 (20.90%)

Canyon Resources

MCap

AUD262m

Last close

AUD0.19

▲ 0.02 (12.12%)

Immix Biopharma

MCap

USD51m

Last close

USD1.82

▲ 0.12 (7.06%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

Overview
Financials
Research
Thematics

Edison Investment Research is terminating coverage on Ryvu Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare |
Outlook

24.02.21

Ryvu Therapeutics — Rebalancing R&D pipeline towards clinical stage

Healthcare |
Update

11.05.20

Ryvu Therapeutics — Diversified pipeline ensures continued newsflow

Healthcare |
Update

23.03.20

Ryvu Therapeutics — Successful Phase I with SEL24/MEN1703

Healthcare |
Update

04.12.19

Ryvu Therapeutics — First ever clinical data from lead assets in 2020

Sector

Healthcare

Financials

Edison Investment Research is terminating coverage on Ryvu Therapeutics. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Outlook

Healthcare

28.11.17

Selvita — New 2017-2021 strategy to boost R&D

Flash note

Healthcare

09.10.17

Selvita — Clinical hold on SEL24

Flash note

Healthcare

28.03.17

Selvita — Menarini Group in-licensed SEL24

Outlook

Healthcare

20.03.17

Selvita — SEL24 enters Phase I/II

Update

Healthcare

22.11.16

Selvita — Update 22 November 2016

Update

Healthcare

14.10.16

Selvita — Update 14 October 2016

Update

Healthcare

22.08.16

Selvita — Update 22 August 2016

Update

Healthcare

17.06.16

Selvita — Update 17 June 2016

Update

Healthcare

25.04.16

Selvita — Update 25 April 2016

Outlook

Healthcare

09.12.15

Selvita — Update 8 December 2015